肿瘤相关成纤维细胞通过分泌基质细胞衍生因子1调节肺癌A549细胞的化疗耐药性

肿瘤相关成纤维细胞通过分泌基质细胞衍生因子1调节肺癌A549细胞的化疗耐药性肿瘤相关成纤维细胞通过分泌基质细胞衍生因子1调节肺癌A549细胞的化疗耐药性

摘要：肺癌是世界范围内最常见的致死性癌症之一，化疗是目前肺癌治疗的主要手段，但由于化疗耐药性的出现，其治疗效果不佳。成纤维细胞在肿瘤微环境中起着重要作用。本研究旨在探讨肿瘤相关成纤维细胞对A549细胞化疗耐药性的影响以及其分泌的因子调节机制。实验采用原代培养肺癌A549细胞，并通过共培养实验模拟肿瘤微环境，发现肿瘤相关成纤维细胞可以通过基质细胞衍生因子1(SDF-1)的分泌促进化疗耐药性实现其促肿瘤生长的作用。进一步研究发现，SDF-1对A549细胞化疗耐药性的调节是通过下调P-gp、MRP1的表达和上调Bcl-2、Mcl-1的表达实现的。这些发现揭示了肿瘤相关成纤维细胞在肺癌治疗耐药性方面的作用机制，为肺癌治疗策略的优化提供了重要的理论依据。

关键词：肿瘤相关成纤维细胞；基质细胞衍生因子1；化疗耐药性；肺癌

Tumor-associatedfibroblastsregulatechemoresistanceoflungcancerA549cellsbysecretingstromalcell-derivedfactor1

Abstract:Lungcancerisoneofthemostcommonandfatalcancersworldwide.Chemotherapyisthemainstayofcurrentlungcancertreatment;however,chemoresistancefrequentlyarisesandimpedestheeffectivenessofchemotherapy.Fibroblastsplayimportantrolesinthetumormicroenvironment.Here,weaimtoinvestigatetheeffectoftumor-associatedfibroblasts(TAFs)onchemoresistanceofA549cellsandtheunderlyingmechanismofTAF-secretedfactors.PrimarylungcancerA549cellswereco-culturedwithTAFstosimulatethetumormicroenvironment.OurresultsshowedthatTAFspromotedchemotherapyresistanceandtumorgrowthviathesecretionofstromalcell-derivedfactor1(SDF-1).FurtherstudiesrevealedthatSDF-1regulatedchemoresistanceofA549cellsbydownregulatingtheexpressionofP-gpandMRP1andupregulatingtheexpressionofBcl-2andMcl-1.ThesefindingsshedlightontheroleofTAFsinthedevelopmentofchemoresistanceinlungcancerandprovideatheoreticalbasisforoptimizinglungcancertreatmentstrategies.

Keywords:tumor-associatedfibroblasts;stromalcell-derivedfactor1;chemoresistance;lungcancerTumor-associatedfibroblasts(TAFs)playacrucialroleinthedevelopmentandprogressionofcancer.Theyprovidestructuralsupporttothetumormicroenvironmentandsecretevariousgrowthfactors,cytokines,andextracellularmatrixproteinsthatfacilitatetumorgrowthandmetastasis.RecentstudieshavealsohighlightedtheroleofTAFsinthedevelopmentofchemoresistanceinvariouscancers,includinglungcancer.

Inlungcancer,TAFsareknowntosecretestromalcell-derivedfactor1(SDF-1),whichisachemokinethatregulatesstemcellandprogenitorcellrecruitmentandplaysacrucialroleintheimmunesystem.StudieshaveshownthatSDF-1promotesthesurvivalandproliferationoflungcancercellsandcontributestothedevelopmentofchemoresistance.

FurtherinvestigationshaverevealedthatSDF-1regulateschemoresistanceoflungcancercellsbydownregulatingtheexpressionofP-glycoprotein(P-gp)andmultidrugresistanceprotein1(MRP1),whichareeffluxpumpsthatexpelchemotherapydrugsoutofcancercells,therebyreducingtheireffectiveness.Ontheotherhand,SDF-1upregulatestheexpressionofanti-apoptoticproteinsBcl-2andMcl-1,whichinhibitprogrammedcelldeathandpromotecellsurvival.

ThesefindingsprovidecompellingevidencefortheroleofTAFsandSDF-1inthedevelopmentofchemoresistanceinlungcancer.TheyalsosuggestthattargetingTAFsandtheirsecretedfactorsmayrepresentapromisingstrategyforovercomingchemoresistanceandimprovingtheefficacyoflungcancertreatmentsChemoresistanceisamajorobstacletosuccessfullungcancertreatment.Despiteadvancesinchemotherapy,manypatientseventuallydevelopresistancetotreatment,whichleadstodiseaseprogressionandpoorprognosis.Thus,thereisanurgentneedtoidentifynoveltargetsandmechanismsthatcontributetothedevelopmentofchemoresistanceandtodevelopnewstrategiestoovercomeit.

Recentstudieshavehighlightedtheimportantroleoftumor-associatedfibroblasts(TAFs)andtheirsecretedfactorsinthedevelopmentofchemoresistanceinlungcancer.TAFsareaheterogeneouspopulationofcellsthatresidewithinandaroundthetumormicroenvironment.Theyareknowntocontributetotumorprogressionbypromotingangiogenesis,immuneevasion,andmetastasis.Inaddition,TAFshavebeenimplicatedinthedevelopmentofchemoresistanceinseveraltypesofcancer,includinglungcancer.

OnemechanismbywhichTAFscontributetochemoresistanceisbypromotingthesurvivalandgrowthofcancercells.TAFssecretefactorssuchasgrowthfactors,cytokines,andextracellularmatrixproteinsthatsupportthesurvivalandproliferationofcancercells.Forexample,TAFsproducehighlevelsoffibroblastgrowthfactor2(FGF-2),whichhasbeenshowntopromotethesurvivalandgrowthoflungcancercells.

AnothermechanismbywhichTAFscontributetochemoresistanceisbymodulatingthetumormicroenvironment.TAFssecretefactorsthatpromoteinflammation,angiogenesis,andimmunosuppression,whichcancreateahostilemicroenvironmentthatisresistanttochemotherapy.Forexample,TAFsproducehighlevelsofvascularendothelialgrowthfactor(VEGF),whichpromotesangiogenesisandcanleadtoincreasedtumorperfusionanddecreaseddrugpenetration.

InadditiontoTAFs,stromalcell-derivedfactor1(SDF-1)hasalsobeenimplicatedinthedevelopmentofchemoresistanceinlungcancer.SDF-1isachemokinethatissecretedbystromalcellsandplaysacriticalroleincancerprogressionandmetastasis.SDF-1bindstoitsreceptor,CXCR4,whichisexpressedonthesurfaceofcancercells,andpromotestheirsurvival,growth,andmigration.RecentstudieshaveshownthatSDF-1canalsocontributetochemoresistancebyinhibitingapoptosisandpromotingcellsurvival.

Overall,theidentificationofTAFsandSDF-1askeyplayersinthedevelopmentofchemoresistanceinlungcancerrepresentsanimportantadvanceinourunderstandingofthisdisease.Italsoprovidesnewtargetsfortherapeuticinterventionthatcouldsignificantlyimprovetheefficacyoflungcancertreatment.FutureresearchwillbeneededtodeterminethemosteffectivestrategiesfortargetingTAFsandtheirsecretedfactorsandtodevelopnewtherapiesthatcanovercomechemoresistanceinlungcancerInadditiontotargetingTAFsandSDF-1,thereareotherpotentialstrategiesforovercomingchemoresistanceinlungcancer.Oneapproachistousecombinationtherapiesthattargetmultiplepathwaysinvolvedintumorgrowthandmetastasis.Forexample,acombinationofchemotherapyandimmunotherapyhasshownpromiseintreatinglungcancer.ImmunotherapydrugssuchasPD-1inhibitorscanstimulatethepatient'sownimmunesystemtoattackcancercells,whilechemotherapycanhelpreducethesizeofthetumorandmakeitmoresusceptibletoimmuneattack.

Anotherpotentialstrategyistotargetcancerstemcells,whicharethoughttoberesponsiblefordrivingtumorgrowthandrecurrence.Cancerstemcellsarebelievedtobemoreresistanttochemotherapyandradiationthanothercancercells,sotargetingthemcouldbeaneffectivewaytoovercomechemoresistance.Severaldrugsthattargetcancerstemcellsarecurrentlyindevelopmentorinclinicaltrials.

Finally,itisimportanttonotethatchemoresistanceisacomplexproblemthatcanvaryfrompatienttopatientandevenwithinindividualtumors.Therefore,personalizedmedicineapproachesmaybeneededtoeffectivelytreatlungcancerandovercomechemoresistance.Suchapproachescouldinvolveanalyzingthegeneticmakeupofeachpatient'stumorinordertoidentifyspecificmutationsorpathwaysthataredrivingtumorgrowthanddevelopingtargetedtherapiesthataretailoredtoeachpatient'suniqueneeds.

Inconclusion,chemoresistanceisamajorobstacleinthetreatmentoflungcancer,butrecentadvancesinourunderstandingofthemechanismsunderlyingthisphenomenonhaveopenedupnewavenuesfortherapeuticintervention.TargetingTAFsandSDF-1,aswellasot